Prothena | PRTA - Sales Revenues

Stock Price
9.76
Daily Change
-0.10 -1.01%
Monthly
-7.22%
Yearly
35.93%
Q2 Forecast
9.47

Prothena reported $51.08M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 392.91M 8.41M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Exelixis USD 610.8M 12.14M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Prothena USD 51.08M 51.06M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xoma USD 25K 5M Sep/2024